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Serum or plasma specimens were assayed in indirect 
immunfluorescence tests on cryostat sections of normal 
human skin for the presence and titer of antibodies 
reactive with human epidermal cytoplasmic antigens. A 
polyva lent fluorescein-labeled goat anti-human immu-
noglobulin antiserum was used in all tests. Three distinct 
s taining patterns w ere noted: upper epidermal cytoplas-
mic fluorescence, U-CYT, produced by antibodies reac-
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Abbreviations: 
BCL: basel cell cytoplasmic flu orescence 
ECA: epidermal cytoplasmic ant igens 
FITC: flu orescein isothiocyanate 
G-CYT: general cytoplasmic fluorescence 
PBS: phospha te-bu ffered saline 
U-CYT: upper epiderma l cytoplasmic flu orescence 
tive with antigen present in cells of the upper and middle 
layers of the epidermis; general cytoplasmic fluores-
cence, G-CYT, produced by antibodies reactive with an-
tigens present in cells throughout the epidermis; and 
basal cell cytoplasmic fluorescence, BCL, produced by 
antibodies reactive with components present only in 
basal cells. Sera from 8% of 52 normal blood dOllors 
produced the U-CYT pattern at dilutions greater than 
1:10. The incidence of antibodies reactive with epidermal 
cytoplasmic antigens in patients with a clinical history 
of not more than 2 basal cell carcinomas of the skin was 
5%, compared to an incidence of 89% in those individuals 
with 3 or more separate instances of skin neoplasms. 
There was no difference in the frequency with which 
cryosurgery was used in the treatment of skin neoplasms 
in either of these 2 groups. Antibodies to epidermal 
cytoplasmic antigens were also detected in 10% of pa-
tients with nondermatologic, nonpulmonary neoplasms, 
in 43% of patients with pulmonary neoplasms a nd in 10f 
11 patients with nonneoplastic diseases. Positive sera 
yielded titers ranging from 1:16 to 1:1024. The most 
common staining patterns noted in all of these cases 
were the U-CYT and G-CYT patterns; the BCL staining 
pattern was noted in only one instance. 
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Ant ibodies which are reactive with several different compo-
nents of normal human skin, including t he intercellulru" sub-
stance antigen [1,2], basement membrane zone antigens [3], 
and stratum corneum antigens [4], have been described. In 
addition, antibodies reactive with epidermal cytoplasmic anti-
gens (ECA) of normal human skin have also been identified. 
These antibodies have been detected in normal individuals 
[5-7], patients with various malignancies [5,7], burn patients 
who had rejected a skin graft [6], bone marrow-transplanted 
patients [8,9] and some individuals with drug reactions [10). 
Three different patterns of human epidermal cytoplasmic 
staining have been recognized by investigators using indu·ect 
immunofluorescence [6-8,11-14). These 3 patterns have been 
defmed as follows [7,13]: (1) upper epidermal cytoplasmic flu-
orescence, abbreviated U -CYT, produced by antibodies reactive 
with antigens present in the cytoplasm of the cells in the upper 
and middle layers of the epidermis, exclusive of the basal cell 
layer (Figure, C); (2) general cytoplasmic fluorescence (G-CYT) 
produced by antibodies reactive with cytoplasmic antigens 
which are present in cells throughout the epidermis (Figure, B); 
and (3) basal cell cytoplasmic fluorescence (BCL) produced by 
antibodies reactive with cytoplasmic components present only 
in the cytoplasm of basal cells of normal human epidermis 
(Figure D) . 
In the present study, serum or plasma samples from normal 
blood donors, patients with skin neoplasms and patients with 
various noncutaneous malignancies and nonmalignant condi-
tions were examined in indirect immunofluorescence tests for 
both the presence and titer of antibodies to human ECp 
FIG Indirect immunofluorescence tests performed with cryostat sec-
tion of normal human skin incubated with (A) normal human serum; 
(B) serum producing the G-CYT staining pattern; (C) serum producing 
the U -CYT staining pattern; and (D) serum producing the BCL staining 
pattern. 
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MATERIALS AND METHODS 
Serum or Plasma Specimens 
Serum or EDTA plasma specimens were collected f.rom four groups 
of individuals: 52 blood donors; 31 patients with skin neoplasms; 80 
pat ients with various noncutaneous malignancies; and 11 patients with 
~onneoplastic conditions. Samples were stored at -20°<;: prior to test-
mg. 
Subslrale 
Human skin specimens obtained by punch biopsy for diagnostic 
purposes and found to be histologically normal a nd free of immuno-
globulins or complement, as determined by immunofluorescence, were 
used as a substrate in indirect immunofluorescence tests. Skin frag-
ments which had been kept moist on a saline-soaked sponge for no 
longer than 20 min were embedded in OTC embedding compound (Lab-
T ek Products, Naperville, ILLinois) , frozen at -40°C and stored at 
-70°C for no longer than 28 days. 
Laboralory Methods 
Four-micron cryostat sections of normal human skin were cut just 
prior to use and allowed to air-dry at room temperature for approxi-
mately 20 min. Sections were flxed in acetone for 5 min at room 
temperature, removed from the fixative and allowed to air dry. Dilu-
tions (1:10) of normal human sera were prepared, using .01 M phosphate-
buffered saline (PBS) , pH 7.5, containing 1% bovine serum albumin, as 
a diluent. Tissue sections were covered with the diluted serum and 
incubated at room temperature in a humid chamber for 45 min. The 
sections were washed twice for 5 min per wash in PBS and covered 
with a 1:100 dilution of polyvalent fluorescein isothiocyanate (FITC)-
labeled goat anti-human immunoglobulin a ntiserum (Atlantic Anti-
bodies, Westbook, Maine), which had an FITC to protein ratio of 2.3 
molar and a total protein concentration of 16 mg/ ml. The sections were 
incubated as described above and were then washed twice with PBS as 
described. Sections were examined by UV microscopy. Those specimens 
which were found to react positively with ECA were t itered to the 
endpoint; the highest dilution yielding visible fluorescence was defined 
as the titer. Titration was begun with samples diluted 1:8. 
ContTols 
Sera which were known to contain ant ibodies capable of producing 
the G-CYT, U-CYT, and BCL staining patterns were included as 
positive controls in each assay. This procedul·e ensured that the ECA 
of the substrate had not deteriorated upon storage. Blocking experi-
ments were performed on ten sera which contained antibodies reactive 
with human ECA. A 1:10 dilution of each of these sera was incubated 
for 45 min at room temperature with cryostat sections of norma l human 
epidermis, washed twice for 5 min per wash in PBS, and incubated for 
45 min with a 1:10 dilution of unlabeled goat anti-human immunoglob-
ulin antiserum (Hyland Laboratories, Costa Mesa, CAl. The slides were 
then washed as described and incubated for 45 min with a 1:100 dilu t ion 
of fluorescein labeled goat a nti-human inlmunoglobulin antiserum . 
After additional washing, the slides were examined as described. 
Statistical Analyses 
Analyses were performed by the Chi-sq uru·e method. 
RESULTS 
Indirect Immunofluorescence Assay 
Fifty-two serum specimens obtained from blood donors were 
assayed in indirect immunofluorescence tests at dilutions of 
1:10 on cryostat sections of normal human epidermis. Of these, 
18% were found to contain antibodies .producing the U-CYT, 
6% the G-CYT and none the BCL staining pattern. However, 
only 8% of the 52 serum specimens yielded positive staining at 
dilutions greater than 1:10; in all of these instances, the U-CYT 
staining pattern was noted (Table). 
The incidence of antibodies reactive with ECA in samples 
from patients with a clinical history of 1 or 2 basal cell carci-
nomas of the skin, was approximately 5%, compared to an 
incidence of 89% in those indivi~uals with 3 or more separate 
instances of skin neoplasms (usually consisting of only basal 
cell carcinomas, but in some cases, of both basal and squamous 
cell carcinomas). This difference was significant (p < 0.005) . 
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TABLE Incidence, patterns and titers of antibodies to hu.man epidermal cytoplasmic antigens in various categories 
Category Mean age 
Cytoplasmic staining paLLerns and titers 
No. Pt ·. No. + %+ 
U-CYT G-CYT BCL 
Blood donors 28 52 4 8 16, 16, 32, 32 
Skin neoplasms (52 separate instances) 51 22 1 5 64 
Skin neoplasms (2:3 sepa1'3te instances) 60 9 8 89 256,64, 32", 256, 16", 16" 
64, 64, 512, 32" 
AdenocaJ'cinoma of the lung 58 10 3 30 512, 128 128 
Oat ce ll carcinoma of the lung 54 4 2 50 256 16 
Squamous cell caJ'cinoma of the lung 58 4 3 75 1024, 64 128 
Large cell carcinoma of the lung 53 5 2 40 256 16 
Adenocarcinoma of the colon 62 35 3 9 64 <, 256,512 16" 
Adenocarcinoma of the rectum 63 9 1 1] 64 
LeiomyosaJ'coma 46 1 1 100 128 
Mesothelioma 36 1 1 100 512 
Gastric ulcer 37 3 1 33 256 
Miscellaneous disorders' 51 19 0 0 
I Those specimens reacting with ECA at dilutions> 1:10 were considered positive. 
2 No reactivity with ECA was noted as dilutions 2: 1:10 with specimens obtained from patients with the following miscellaneous disorders: 
metastatic SaJ'coma (1); adenocaJ'cinoma of the common bile duct (J); adenocarcinoma of the endometrium (1); parotid gland tumor (2); 
adenocarcinoma of the breast (4); pancreatic caJ'cinoma (2); actinic keratosis (5); fibrocystic disease of the breast (1); acute and chronic cystitis 
(1); cholecystitis and cholelithiasis (1). 
". I,. "Superscript letters identify those samples yielding more than one staining patterns. 
The most common staining pattern was the U-CYT pattern; 
positive sera yielded titers ranging from 1:16 to 1:512. 
Of 80 patients with nondermatologic malignancies, 16 were 
found to have antibodies reactive with ECA. Approximately 
60% of the positive samples contained antibodies producing the 
U -CYT and 40% the G-CYT staining pattern; titers ranged 
from 1:16 to 1:1024. Twenty-three of the 80 patients with 
nondermatologic malignancies had pulmonary neoplasms; of 
these 23 patients, samples from 10 were positive for antibody to 
ECA; 60% yielded the U-CYT and 40% the G-CYT staining 
pattern. Of the remaining 57 patients in this category, 6 were 
found to have antibodies to ECA; samples from 50% yielded the 
U-CYT, 17% the G-CYT, 17%.the BCL and 16% yielded both 
the U-CYT and G-CYT staining patterns. Of 11 patients with 
nonneoplastic diseases, one was found to have antibodies pro-
ducing the U-CYT staining pattern. 
The fluorescent staining patterns observed were considered 
to reflect specific binding of human immunoglobulins to ECA. 
Cryostat sections of normal human epidermis were incubated 
first with sera found to contain antibodies to ECA, followed by 
an incubation with unlabelled goat anti-human immunoglobu-
lin antiserum. The subsequent binding of FITC- labeled goat 
anti-human immunoglobulin antiserum was blocked by the 
unlabeled goat anti-human immunoglobulin antiserum. 
Therapy 
Cryosurgery was used to treat the skin neoplasms of 21 of 
the 22 patients with one or 2 tumors; surgical excision was used 
to treat the remaining patient. Of 9 patients with a history of 3 
or more skin neoplasms, cryosurgery was used to treat at least 
3 skin neoplasms on at least 3 separate occasions in each of the 
9 patients in this category. Ofthe 80 patients with noncutaneous 
malignancies, 15 were receiving chemotherapeutic agents at the 
time serum or plasma specimens were obtained. Of these 15 
patients, 27% were found to possess antibodies reactive with 
ECA. Of the 65 patients who were not receiving chemoth erapy, 
17% were found to possess antibodies reactive with ECA 
(p>0.75). 
DISCUSSION 
The existence of at least 3 distinct epidermal cytoplasmic 
antigens has been demonstrated in most, if not all human skin 
by several investigators [5,7,12,13]. Low titer antibodies to these 
antigens were noted in 24% of 52 normal blood donors examined 
in this study; values of 7% [5] and 34% [7] have been reported 
by others. The results of the present study suggest that both 
the incidence and titer of antibodies reactive with human ECA 
appear to be greater in patients with repeated episodes of skin 
neoplasms compared to normal blood donors or those with a 
history of one or two episodes of skin neoplasms. Serum speci-
mens from 89% of patients with repeated episodes of skin 
neoplasms produced the U -CYT staining pattern; 2 of t he sera 
also produced the G-CYT staining pattern. In contrast only 1 
of 22 samples from patients with 1 or 2 instances of basal cell 
carcinomas of the skin contained antibodies reacting with ECA. 
The reason for this disparity is uncertain. Possibly, t he repeated 
use of cryosUJ-gery in the treatment of skin tumors may have a 
role in inducing these antibodies. Cryosurgical prostatectomy 
has been reported to result in the formation of antibodies 
reactive with cytoplasmic constituents of secretory epithelial 
cells of human prostate [15,16]. Similarly, Bagley and Faraci 
observed that mice with 3-methylcholantlu-ene-induced fibro-
sarcomas which were treated with either cryosurgery or elec-
trocauterization had significantly greater humoral and cell me-
diated immunity to t heir tumor, as compared to those animals 
whose tumors were untreated or were surgically removed [17]. 
In the present study, cryosurgery was repeatedly used to 
treat the tumors of the nine patients with a history of 3 or more 
skin neoplasms. This treatment may have resulted in the release 
of epidermal antigens and repeated exposure of the host to 
epidermal antigens may have induced the formation of anti-
bodies reactive with ECA. Whether other forms of trauma are 
responsible for the induction of antibodies to ECA in normal 
subjects is not known. Saurat et al observed the presence of 
antibodies to ECA in 88% of 17 bone marrow transplant patients 
[8,9]. Since skin lesions occur commonly after bone marrow 
transplantation [18], it was suggested that antibodies to ECA 
may develop as a result of chronic skin damage accompanied 
by release of epidermal antigens. Of the 80 patients with non-
cutaneous malignancies included in this study, 65 were not 
receiving chemotherapy at the time serum or plasma specimens 
were obtained. Antibodies to ECA were detected in 17% of 
these 65 patients and in 27% of t he 15 patients who were 
receiving chemotherapy. This difference was not statistically 
significant (p >.75). Therefore, it seems unlikely that antibodies 
to ECA observed in patients with non cutaneous malignancies 
included in this study were drug-induced. Furthermore, chemo-
therapy did not appear to interfere with the expression of 
antibodies to ECA. 
Although sera from patients with malignant melanoma were 
not examined in the present study, Abel and Bystryn reported 
that 34% to 53% of patients with malignant melanoma had 
circulating antibodies which produced the U-CYT staining 
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pattern [7]. These antibodies were noted to be presen t in 
patients with malignant melanoma in a frequency 2.5 times that 
observed in normal individuals. No correlation was observed 
between stage of disease and incidence of anti-ECA antibod ies. 
However, the sera in this study were examined at a 1:5 dilution, 
with no attempt being made to determine the antibody titers of 
those sera which were found to react positively in indirect 
immunofluorescence tests. 
The finding of antibodies reactive with ECA is not restricted 
to patients with skin neoplasms but has also been reported in 
patients with other malignancies. Bystryn, Abel and Weidman 
reported the presence of antibodies reactive with ECA in 32% 
of 34 patients with various malignancies [5]. Similarly, the 
results of the present study indicate that antibodies reactive 
with ECA exist in patients with malignancies; these antibodies 
were found in 19% of patients with noncutaneous malignancies. 
Of 23 patients with pulmonary neoplasms, 43% were found to 
have anti-ECA antibodies, compared to an incidence of only 9% 
in 35 patients with adenocarcinoma of the colon (p < .01). 
Although sera from patients with other neoplasms were also 
examined, the small number of cases precludes an accurate 
estimate of the incidence of anti ECA antibodies. 
Antibodies reactive with t he basal cell layer of human epi-
dermis were found in the sera of 13% of 24 bum victims [19] 
and in 16% of 42 patients with drug reactions involving the skin 
[10]. T hese antibodies have also been noted in patients with 
pemphigus and bullous pemphigoid; in these patients, titers 
ranged from 1:40 to 1:1280 [11]. In the current study, one 
patient with adenocarcinoma of the rectum was found to have 
circulating antibodies reacting with the cytoplasm of human 
epidermal basal cells. Sera containing antibodies responsible 
for the BCL staining pattern continue to produce t his pattern 
after absorption with A and B blood group substances [6]. 
Antisera directed against blood group substances A and B do 
react with human epidermis, but the pattern resembles the 
staining produced by sera from patients with pemphigus [20]. 
Finally, basal cells have been shown to lack A and B blood 
group antigens [21], making it still less likely that th e BCL 
staining pattern is attributable to these substances. 
Epidermal cytoplasmic antigens also do not appear to be 
HLA antigens, since the latter are distributed on the cell surface 
rather than intracellularly [22]. Support for the concept that 
some of the ECA may be differentiation antigens comes from 
the work of Bystryn and Frances [23]. These investigators 
noted that sera which produced the U -CYT or BCL staining 
patterns with normal human skin as substrate did not react 
with the cytoplasm of all basal or squamous cell carcinomas of 
the skin. In contrast, sera producing th e G-CYT staining pattern 
reacted with the cytoplasm of all basal and squamous cell 
carcinomas of the skin. T hese findings suggest that malignant 
transfo~mation of cells in the epidermis may, in some cases, 
result 111 a loss of antigens which are associated with the 
differentiation of epidermal cells (ie, those antigens responsible 
for the U-CYT and BCL staining patterns). Additional evidence 
in support of ECA being differentiation antigens is provided by 
the work of Saurat et al [9]. Using the technique of indirect 
immunofluorescence, performed on cryostat sections of rabbit 
lip, sera containing antibodies reactive with ECA were found 
not to react identically on mucosal, parakeratotic and ortho-
keratotic epithelium. T hese results suggest that ECA are in-
volve.d in keratinocyte differentiation. 
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Although the present study did not determine the immuno-
globulin classes of the antibodies reactive with ECA, other 
investigators h ave reported them to be of the IgG class [8-10]. 
Whether the antibodies which react with ECA are auto- or 
isoantibodies is unknown. In one instance, a patient's serum 
produced the BCL staining pattern in indirect immunofluores-
cence tests with allogenic normal human epidermis, but did not 
react with autologous skin [11]. 
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